Navigation Links
CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Date:10/17/2011

RESEARCH TRIANGLE PARK, N.C., Oct. 17, 2011 /PRNewswire/ -- Max Neeman International is the only CRO in India to manage hemophilia trials according to the Clinical Trials Registry-India (CTRI). Of the total hemophilia trials currently being conducted in India, Max Neeman can boast supporting 80% of these with the remaining conducted by pharma companies. Max Neeman International has established a team of experts specialized in carrying out hemophilia trials in response to sponsor demand. The team has the required expertise via involvement of academia with industry, hemophilia trial experience and extensive database of best Investigators for indication to develop innovative approaches to optimize complex study design.  Often strict inclusion/exclusion criteria and data analysis for such studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Max Neeman is a leading CRO in India that has a focus on hemophilia and bleeding disorder studies, in addition to other indications.  Patient enrollment for complex global and multi-centric hemophilia trials is challenging because potential subjects are fewer in number and widely dispersed. With an Incidence of 1 in 10,000 people, India has more than 120,000 hemophilic and thus it has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 & ISO 27001:2005 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 31 cities with 6 regional offices.  For more information, please contact Donald Swankie, Vice President of Business Development at +1.919.424.3345 / donald.swankie@neeman-medical.com or visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
3. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
4. Mylan Confirms Four First-to-File Challenges
5. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
8. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
11. Analysis confirms that nano-related research has strong multidisciplinary roots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... separable adhesive layers, as issued by the U.S. Patent & Trademark Office (USPTO). ... to combining electronics and health monitoring. This invention will be critical to the ...
(Date:3/29/2017)...  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions ... results for the fourth quarter and full year ... a pivotal year for us with our first ... agreements, major reimbursement progress with Medicare, positive medical ... addition we cleared our 2 nd generation ...
(Date:3/29/2017)... year,s petition to the White House signed by 120,000 ... generate awareness on the importance of new organic medicines and nutritional ... place. ... this month Health Advance (OTC PINK: HADV ), ... announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... announce that Nerium International Mexico has been approved as an active member of ... achieve satisfaction and protection among distributers and consumers in relationship marketing. This professional ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):